Medicine and Dentistry
Patient
100%
Acetylcysteine
98%
Antioxidant
84%
Inpatient
83%
Vasculotropin
82%
Antioxidant Capacity
73%
Leukemia Cell
73%
Contrast-Induced Nephropathy
73%
B-Cell Chronic Lymphocytic Leukemia
73%
Cardiovascular System
73%
Platelet
66%
Endothelial Cell
64%
Cells
61%
Plasma
60%
Nitric Oxide
56%
Endothelial Dysfunction
54%
Randomized Controlled Trial
51%
Diabetes
51%
Ingestion
49%
Glucose
45%
Chronic Kidney Disease
43%
Volunteer
39%
Monocyte
34%
Placebo
34%
Culture
32%
Mediator
31%
Conjugation
30%
Glutathione
29%
In Vitro
28%
Older Adult
28%
Amaurosis
27%
Man
27%
Angiography
26%
Iodixanol
26%
Infusion
25%
Contrast Medium
24%
Venom
24%
Bone Marrow Transplantation
24%
Granulocyte
24%
Hemodialysis
24%
Fructose
24%
Iohexol
24%
Bone Marrow
24%
Group Trial
24%
Human
24%
Blood Clotting
24%
Antiapoptotic
24%
B Lymphocyte Receptor
24%
Protein Kinase
24%
Patient with Type 2 Diabetes
24%
Pharmacology, Toxicology and Pharmaceutical Science
Oxidized Low Density Lipoprotein
37%
Vasculotropin
33%
Diabetes Mellitus
30%
Glucose
28%
Venom
24%
Hemodialysis
24%
12 Hydroxyicosatetraenoic Acid
24%
Antioxidant
24%
End Stage Renal Disease
24%
Non Insulin Dependent Diabetes Mellitus
24%
Human
24%
Bioavailability
24%
Diesel Exhaust
24%
Rat
24%
Inhalation
24%
Prostate Carcinoma
24%
Endothelial Dysfunction
24%
Nitric Oxide
24%
Cohort Study
24%
Insulin
24%
Hypoxia
24%
Acetylsalicylic Acid
24%
Collagen
13%
Thromboxane A2
12%
Biochemistry, Genetics and Molecular Biology
Ingestion
49%
Vascular Endothelial Growth Factor
49%
Glucose
35%
Platelet
24%
Acetylcysteine
24%
Bioenergy
24%
Rat
24%
Health
24%
Human
24%
Contrast
24%
Clinical Research
24%
12-Hydroxyeicosatetraenoic Acid
24%
Calorie
18%
Fat
16%
Low-Density Lipoprotein
15%
Angiogenesis
14%
Thromboxane A2
12%
Hyperglycemia
10%